Creo Medical ((GB:CREO)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The clinical study titled ‘Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue’ aims to evaluate the safety and feasibility of the Creo Medical MicroBlate™ Flex AB1 instrument. This study is significant as it targets patients with peripheral lung nodules, offering a potential alternative to surgical resection for those who are medically inoperable or have declined surgery.
The intervention being tested is a device named Ablation, specifically designed for bronchoscopic microwave ablation of lung nodules. This device aims to offer a minimally invasive treatment option for lung cancer patients.
The study is observational with a cohort model and a prospective time perspective. It does not involve allocation or masking, focusing primarily on observing the outcomes of the intervention in a real-world setting.
The study began on February 27, 2023, with an estimated completion date of April 4, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence clinical practices and market dynamics.
The update on this study could positively impact Creo Medical’s stock performance by enhancing investor confidence in the company’s innovative solutions for lung cancer treatment. This development positions Creo Medical favorably within the medical device industry, potentially setting it apart from competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.